Idelalisib decreased CLL cell adhesion to TNFα-activated HUVEC from 23.3% (±2.6%) to 13.9% (±2.4%) at low shear force of 15 dynes/cm2 (p<0.05, n=5). Here, TNF is linked to B-cell chronic lymphocytic leukemia.